Novel Drug Delivery Systems for Releasing Growth Factors to the CNS: Focus on Alzheimer's and Parkinson's Diseases

被引：1

作者：

Herran, E. ^{[1
,2
]}

Igartua, M. ^{[1
,2
]}

Pedraz, J. L. ^{[1
,2
]}

Hernandez, R. M. ^{[1
,2
]}

机构：

[1] Univ Basque Country, UPV EHU, Sch Pharm, Lab Pharmaceut,NanoBioCel Grp, Vitoria 01006, Spain

[2] Biomed Res Networking Ctr Bioengn Biomat & Nanome, Vitoria, Spain

来源：

MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2014年 / 14卷 / 07期

关键词：

Alzheimer's disease; central nervous system; drug delivery systems; GDNF; Parkinson's disease; VEGF; CENTRAL-NERVOUS-SYSTEM; BLOOD-BRAIN-BARRIER; NEURAL STEM-CELLS; NEUROTROPHIC FACTOR; INTRANASAL DELIVERY; GENE-THERAPY; IN-VIVO; BEHAVIORAL RECOVERY; SECRETING CELLS; MOUSE MODEL;

D O I：

10.2174/1389557514666140622205058

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Alzheimer's disease (AD) and Parkinson's disease (PD) represent the most common neurodegenerative disorders and affect more than 35 million people. Due to the limited effectiveness of available treatments in halting the neurodegenerative process, new therapies, such therapies based on growth factors (GFs), have been investigated. Nevertheless, the efficacies of these new treatments depend not only on the application of neurotrophins but also on the approaches used to deliver these proteins such that they can reach the brain. This review summarises the most widely used drug delivery systems (DDSs) for releasing GFs as possible treatments for AD and PD.

引用

页码：557 / 566

页数：10

共 50 条

[21] Nanotechnology-based drug delivery systems for the treatment of Alzheimer's disease
Fonseca-Santos, Bruno
Daflon Gremiao, Maria Palmira
Chorilli, Marlus
INTERNATIONAL JOURNAL OF NANOMEDICINE, 2015, 10 : 4981 - 5003
[22] Nanocarrier mediated drug delivery as an impeccable therapeutic approach against Alzheimer's disease
Taliyan, Rajeev
Kakoty, Violina
Sarathlal, K. C.
Kharavtekar, Sanskruti Santosh
Karennanavar, Chandrashekar R.
Choudhary, Yogendra Kumar
Singhvi, Gautam
Riadi, Yassine
Dubey, Sunil Kumar
Kesharwani, Prashant
JOURNAL OF CONTROLLED RELEASE, 2022, 343 : 528 - 550
[23] Infiltration of immune cells to the brain and its relation to the pathogenesis of Alzheimer's and Parkinson's diseases
Netzahualcoyotzi, Citlalli
Santillan-Cigales, Juan Jair
Adalid-Peralta, Laura Virginia
Velasco, Ivan
JOURNAL OF NEUROCHEMISTRY, 2024, 168 (09) : 2316 - 2334
[24] Drug Development for Alzheimer's and Parkinson's Disease: Where Do We Go Now?
Sequeira, Lisa
Benfeito, Sofia
Fernandes, Carlos
Lima, Ines
Peixoto, Joana
Alves, Catarina
Machado, Claudia Sofia
Gaspar, Alexandra
Borges, Fernanda
Chavarria, Daniel
PHARMACEUTICS, 2024, 16 (06)
[25] Inflammatory Process in Alzheimer's and Parkinson's Diseases: Central Role of Cytokines
Alam, Qamre
Alam, Mohammad Zubair
Mushtaq, Gohar
Damanhouri, Ghazi A.
Rasool, Mahmood
Kamal, Mohammad Amjad
Haque, Absarul
CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (05) : 541 - 548
[26] Peripheral Chemo-Cytokine Profiles in Alzheimer's and Parkinson's Diseases
Reale, M.
Greig, N. H.
Kamal, M. A.
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2009, 9 (10) : 1229 - 1241
[27] Nanotechnology-based drug delivery of ropinirole for Parkinson's disease
Barcia, Emilia
Boeva, Liudmila
Garcia-Garcia, Luis
Slowing, Karla
Fernandez-Carballido, Ana
Casanova, Yaquelyn
Negro, Sofia
DRUG DELIVERY, 2017, 24 (01) : 1112 - 1123
[28] Fetal programming of Parkinson's and Alzheimer's diseases: the role of epigenetic factors
Piras, Monica
Fanos, Vassilios
Ravarino, Alberto
Marcialis, Maria Antonietta
Vinci, Laura
Pintus, Maria Cristina
Faa, Gavino
JOURNAL OF PEDIATRIC AND NEONATAL INDIVIDUALIZED MEDICINE, 2014, 3 (02):
[29] Proteomics in animal models of Alzheimer's and Parkinson's diseases
Sowell, Rena A.
Owen, Joshua B.
Butterfield, D. Allan
AGEING RESEARCH REVIEWS, 2009, 8 (01) : 1 - 17
[30] Pharmacogenomics of Alzheimer's and Parkinson's diseases
Cacabelos, Ramon
NEUROSCIENCE LETTERS, 2020, 726

← 1 2 3 4 5 →